Candel Therapeutics (CADL) Equity Ratio (2020 - 2025)

Candel Therapeutics' Equity Ratio history runs 6 years deep, the most recent figure standing at 0.41 for Q4 2025.

• In Q4 2025, Equity Ratio fell 33.18% year-over-year to 0.41; the TTM figure through Dec 2025 stood at 0.41 (down 33.18% YoY), while the FY2025 annual figure was 0.41, down 33.18% from the prior year.
• Equity Ratio came in at 0.41 for Q4 2025 at Candel Therapeutics, down from 0.86 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q3 2025 to a low of 1.4 in Q2 2021.
• A 5-year average of 0.37 and a median of 0.61 in 2022 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio sank 254.19% in 2024 and soared 326.1% in 2025, its largest moves.
• Candel Therapeutics' Equity Ratio stood at 0.72 in 2021, then slipped by 14.58% to 0.61 in 2022, then tumbled by 49.63% to 0.31 in 2023, then soared by 100.64% to 0.62 in 2024, then sank by 33.18% to 0.41 in 2025.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.41, 0.86, and 0.85 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison